Literature DB >> 11129112

Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats.

M L Wadenberg1, P Hertel, R Fernholm, K Hygge Blakeman, S Ahlenius, T H Svensson.   

Abstract

Blockade of central alpha1-adrenoceptors has been implicated as a possible factor contributing to the atypical antipsychotic profile of clozapine. Thus, in the present study we examined the effects of concomitant alpha1-adrenoceptor and dopamine D2 receptor blockade on conditioned avoidance response performance, as an index of antipsychotic-like activity, and on the induction of catalepsy, as a test for extrapyramidal side effect liability, in rats. It was found that pretreatment with the alpha1-adrenoceptor antagonist prazosin (0.2mg kg(-1) s.c.) caused an enhancement of a suppression of conditioned avoidance response in the presence of the dopamine D2 receptor antagonist raclopride (0.05-0.20 mg kg(-1) s.c.). The effect was most prominent at a subthreshold dose of raclopride (0.05 mg kg(-1)). At these doses, prazosin or raclopride by themselves, or in combination, did not produce catalepsy. In addition, pretreatment with prazosin (0.2mgkg(-1) s.c.) did not alter the catalepsy produced by a higher dose of raclopride (1.0 mg kg(-1) s.c.). It is suggested that, in the presence of low dopamine D2 receptor occupancy, additional alpha1-adrenoceptor blockade might improve antipsychotic efficacy, and thereby improve the therapeutic window with regard to parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129112     DOI: 10.1007/s007020070036

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  11 in total

1.  ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.

Authors:  M Kołaczkowski; P Mierzejewski; P Bieńkowski; A Wesołowska; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

2.  The role of dopaminergic transmission through D1-like and D2-like receptors in amphetamine-induced rat ultrasonic vocalizations.

Authors:  Jennifer M Wright; May R S Dobosiewicz; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2012-09-28       Impact factor: 4.530

3.  Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain.

Authors:  Jérôme Maheux; Laura Vuillier; Mylène Mahfouz; Claude Rouillard; Daniel Lévesque
Journal:  Int J Neuropsychopharmacol       Date:  2011-04-28       Impact factor: 5.176

4.  Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist.

Authors:  P D Shilling; G Melendez; K Priebe; E Richelson; D Feifel
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

5.  Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function.

Authors:  Z Nourian; T Mow; D Muftic; S Burek; M L Pedersen; J Matz; M J Mulvany
Journal:  Psychopharmacology (Berl)       Date:  2008-06-10       Impact factor: 4.530

6.  Increased plasma norepinephrine concentration in psychotic depression.

Authors:  Jaap G Goekoop; Remco F P de Winter; Ron Wolterbeek; Godfried M J Van Kempen; Victor M Wiegant
Journal:  Ther Adv Psychopharmacol       Date:  2012-04

7.  Dopaminergic modulation of GABAergic transmission in the entorhinal cortex: concerted roles of α1 adrenoreceptors, inward rectifier K⁺, and T-type Ca²⁺ channels.

Authors:  Nicholas I Cilz; Lalitha Kurada; Binqi Hu; Saobo Lei
Journal:  Cereb Cortex       Date:  2013-07-10       Impact factor: 5.357

8.  Alterations in prefrontal glutamatergic and noradrenergic systems following MK-801 administration in rats prenatally exposed to methylazoxymethanol at gestational day 17.

Authors:  Isabelle Léna; Aline Chessel; Gwenaëlle Le Pen; Marie-Odile Krebs; René Garcia
Journal:  Psychopharmacology (Berl)       Date:  2007-02-06       Impact factor: 4.415

9.  Adjunctive treatment with mianserin enhances effects of raclopride on cortical dopamine output and, in parallel, its antipsychotic-like effect.

Authors:  Charlotte Wiker; Love Linnér; Marie-Louise Wadenberg; Torgny H Svensson
Journal:  Neuropsychiatr Dis Treat       Date:  2005-12       Impact factor: 2.570

10.  Adjunctive treatment with mianserin enhances effects of raclopride on cortical dopamine output and, in parallel, its antipsychotic-like effect.

Authors:  Charlotte Wiker; Love Linnér; Marie-Louise Wadenberg; Torgny H Svensson
Journal:  Neuropsychiatr Dis Treat       Date:  2005-09       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.